MannKind's 1Q loss narrows on lower costs

By Associated Press May 5, 2008 Comments (0)

0 Recommendations

Biotechnology company MannKind Corp. said Monday its first-quarter loss narrowed on lower research and development costs.

The company lost $71.4 million, or 70 cents per share, compared with a loss of $73.1 million, or $1 per share, during the same period a year prior. Revenue rose to $20,000 from $10,000. During the most recent period, MannKind had about 28 million additional shares of common stock outstanding.

Analysts polled by Thomson Financial expected a loss of 79 cents per share, with no revenue.

Research and development expenses fell by 8 percent to $58.4 million, more than offsetting a 15 percent rise to $15.7 million in general and administrative expenses.

Shares rose 4 cents to close at $2.55.

Comments (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.

Be the first one to comment on this article.

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.